Intracellular signalling mechanisms in thyroid cancer
| Autor: | Aura Erazo Valle-Solís, Rosa Isela Luna-Ceballos, José Gutiérrez-Salinas, Paul Mondragón-Terán, Luz Berenice López-Hernández, Juan Antonio Suárez-Cuenca |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
MAPK/ERK pathway endocrine system diseases Ocean Engineering BRAF mutations Thyroid cancer Proto-Oncogene Proteins B-raf Papillary thyroid cancer 03 medical and health sciences Cinasas de proteínas activadas por mitógenos MAPK 0302 clinical medicine medicine business.industry Effector Cancer Mutaciones BRAF medicine.disease Hedgehog signaling pathway 030104 developmental biology 030220 oncology & carcinogenesis Cancer research Cáncer de tiroides Mitogenactivated protein kinase MAPK Signal transduction business |
| Zdroj: | Cirugía y Cirujanos (English Edition). 84(5):434-443 |
| ISSN: | 2444-0507 |
| DOI: | 10.1016/j.circen.2016.08.011 |
| Popis: | Background Thyroid cancer is the most common malignancy of the endocrine system, the papillary variant accounts for 80–90% of all diagnosed cases. In the development of papillary thyroid cancer, BRAF and RAS genes are mainly affected, resulting in a modification of the system of intracellular signalling proteins known as “protein kinase mitogen-activated” (MAPK) which consist of “modules” of internal signalling proteins (Receptor/Ras/Raf/MEK/ERK) from the cell membrane to the nucleus. In thyroid cancer, these signanling proteins regulate diverse cellular processes such as differentiation, growth, development and apoptosis. MAPK play an important role in the pathogenesis of thyroid cancer as they are used as molecular biomarkers for diagnostic, prognostic and as possible therapeutic molecular targets. Mutations in BRAF gene have been correlated with poor response to treatment with traditional chemotherapy and as an indicator of poor prognosis. Objective To review the molecular mechanisms involved in intracellular signalling of BRAF and RAS genes in thyroid cancer. Conclusions Molecular therapy research is in progress for this type of cancer as new molecules have been developed in order to inhibit any of the components of the signalling pathway (RET/PTC)/Ras/Raf/MEK/ERK; with special emphasis on the (RET/PTC)/Ras/Raf section, which is a major effector of ERK pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|